Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 26, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not contain financial performance data.
Material Changes and Transactions
The filing details the following transactions executed on February 21, 2007, and notified on February 26, 2007:
- Share Transfer: Abacus (GSK) Trustees Limited transferred 8,711 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Share Exchange: The GSK Trust exchanged 10,735,474 Ordinary Shares for 5,367,737 ADRs.
- ADR Sale: The GSK Trust sold 5,367,737 ADRs at a price of $58.00 per ADR.
- ADR Purchase: Abacus Corporate Trustees Limited (GSK US Trust) purchased 5,367,737 ADRs at a price of $58.00 per ADR.
Management Commentary and Risks
The filing clarifies the nature of the trusts involved:
- GSK Trust: A discretionary trust for current and former employees of GlaxoSmithKline plc and subsidiaries. Directors Dr. J-P Garnier, Dr. M M Slaoui, and Mr. J S Heslop hold interests in this trust similarly to other employees.
- GSK US Trust: A grantor trust for current and former employees of SmithKline Beecham Corporation and subsidiaries. Directors Dr. J-P Garnier and Dr. M M Slaoui hold interests in this trust similarly to other employees.
No specific risks, contingencies, or unusual items beyond the standard disclosure of director interests are mentioned.
Investor Verification Checklist
- Verify the total volume of ADRs traded (5,367,737) and the transaction price ($58.00) against market data for February 21, 2007.
- Confirm the impact of the 8,711 Ordinary Shares transferred to the Employee Share Option Plan on outstanding share counts.
- Review the specific roles of Directors Dr. J-P Garnier, Dr. M M Slaoui, and Mr. J S Heslop to understand their indirect exposure to the trust holdings.
- Note that this filing does not contain financial results; refer to the company's Form 20-F or quarterly reports for performance metrics.